Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | CD44 | P16070 | 2/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501455 | 0.76 | OPRL1 (0.35) | — | |
| SCHEMBL16353671 | 0.75 | HTR2C (0.47) | HTR2ACD44PNMTMAOBHTR2C | |
| Hydrochloric Acid SCHEMBL16353822 | 0.73 | HTR2C (0.46) | HTR2ACD44PNMTMAOBHTR2C | |
| SCHEMBL18440762 | 0.71 | HTR2C (0.41) | CD44PNMTMAOBHTR2C | |
| SCHEMBL5138055 | 0.69 | PARP1 (0.43) | — | |
| SCHEMBL4510414 | 0.68 | OPRM1 (0.35) | — | |
| SCHEMBL18440616 | 0.68 | HTR2C (0.40) | HTR2ACD44PNMTMAOBSLC18A3 | |
| SCHEMBL18495112 | 0.68 | HTR2C (0.40) | HTR2ACD44PNMTMAOBSLC18A3 | |
| SCHEMBL29791584 | 0.68 | HTR2C (0.40) | HTR2ACD44PNMTMAOBSLC18A3 | |
| SCHEMBL18494284 | 0.68 | HTR2C (0.40) | HTR2ACD44PNMTMAOBSLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138333-B2 | Sulfonyl-indole derivatives | PROXIMAGEN LIMITED (GB) | 2012-03-20 | — | — | US | disclosed |
| US-20080293694-A1 | New compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293694-A1 | New compounds | HTR6, HTR1A, HTR1B | HTR2A 9/4885CD44 3895/4885PNMT 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.